Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Journal of Cancer Research and Clinical Oncology|September 14, 2016
Current status in cancer cell reprogramming and its clinical implicationsKenan Izgi, Halit Canatan, Banu Iskender
Molecular and Cellular Biochemistry|April 2, 2016
Novel anti-cancer agent myrtucommulone-A and thymoquinone abrogate epithelial-mesenchymal transition in cancer cells mainly through the inhibition of PI3K/AKT signalling axisBanu Iskender, Kenan Izgi, Halit Canatan
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|July 27, 2016
Reprogramming bladder cancer cells for studying cancer initiation and progressionBanu Iskender, Kenan Izgi, Halit Canatan
Journal of Natural Medicines|June 10, 2015
Myrtucommulone-A treatment decreases pluripotency- and multipotency-associated marker expression in bladder cancer cell line HTB-9Banu Iskender, Kenan Izgi, Halit Karaca, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|September 4, 2015
Priming hMSCs with a putative anti-cancer compound, myrtucommulone-a: a way to harness hMSC cytokine expression via modulating PI3K/Akt pathway?Banu Iskender, Kenan Izgi, Cagri Sakalar, et al.
Tissue Engineering and Regenerative Medicine|January 4, 2019
Long Term Exposure to Myrtucommulone-A Changes CD105 Expression and Differentiation Potential of Mesenchymal Stem CellsKenan Izgi, Mehmet Fatih Sonmez, Halit Canatan, et al.
European Cytokine Network|November 11, 2015
Evaluation of two different adjuvants with immunogenic uroplakin 3A-derived peptide for their ability to evoke an immune response in miceKenan Izgi, Banu Iskender, Cagri Sakalar, et al.
Anti-Cancer Agents in Medicinal Chemistry|April 5, 2016
Effects of Epirubicin and Cisplatin Against 4T1 Breast Cancer Cells are Enhanced by Myrtucommulone-AKenan Izgi, Banu Iskender, Cagri Sakalar, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|January 1, 2016
Inhibition of epithelial-mesenchymal transition in bladder cancer cells via modulation of mTOR signallingBanu Iskender, Kenan Izgi, Esra Hizar, et al.
American Journal of Physiology. Renal Physiology|September 12, 2014
Chronic pelvic allodynia is mediated by CCL2 through mast cells in an experimental autoimmune cystitis modelFuat Bicer, Cengiz Z Altuntas, Kenan Izgi, et al.
Pageof 2